BSX makes a smart acquisition

Article Excerpt

BOSTON SCIENTIFIC CORP., $44.47, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (www.bostonscientific.com; Shares outstanding: 1.4 billion; Market cap: $62.8 billion; No dividends paid) is now buying Mississauga, Ontario-based Baylis Medical for $1.75 billion. The acquisition expands Boston Scientific’s electrophysiology and structural heart products. Baylis offers a novel FDA-approved procedure to make left heart procedures much easier and safer. Meanwhile, Boston Scientific’s overall outlook is positive. Ongoing clinical trials and an active development pipeline are poised to generate further growth opportunities. Boston Scientific is a buy. buy…